The Impact of COVID-19 Infection on the Development of Stroke, Pulmonary Embolism, and Myocardial Infarction: A...

Area of Science:

• Cardiology
• Neurology
• Infectious Diseases

Background:

• Thromboembolic disease development timing relative to viral exposure is crucial.
• Understanding post-infection and post-vaccination thrombotic event timelines is essential.

Purpose of the Study:

• To compare the onset of thromboembolic diseases (myocardial infarction, pulmonary embolism, ischemic stroke) before, during, and after the COVID-19 pandemic.
• To analyze the time intervals between viral infection/vaccination and the development of these conditions.
• To evaluate the prognostic implications of these events.

Main Methods:

• Retrospective analysis of medical records for patients diagnosed with myocardial infarction, pulmonary embolism, or ischemic stroke.
• Data collection included COVID-19 status, vaccination details, time to event onset, and patient outcomes.
• Statistical analysis to compare event timing and mortality rates across different periods and exposures.

Main Results:

• Myocardial infarction patients experienced longer intervals post-infection versus post-vaccination for embolism.
• A higher rate of BioNTech vaccination was observed in MI patients during normalization compared to Sinovac.
• Shorter post-vaccination embolism times were noted in stroke patients during the pandemic.
• Both infection and vaccination increased mortality in stroke and pulmonary embolism patients.

Conclusions:

• Thromboembolic events manifest with variable timing and frequency following viral exposure.
• Viral contact, including COVID-19, can act as a significant triggering factor for thrombosis.
• The multifactorial nature of thrombosis suggests a complex interplay between viral exposure and underlying risk factors.